Novel therapeutic agents: Alvimopan, a novel, peripherally-acting, mu-opioid receptor antagonist for the management of opioid-induced bowel dysfunction (OBD): Positive results from a phase III randomized, placebo-controlled, 21-day trial
D. Paulson, D. Kennedy, R. Donovick, R. Carpenter, M. Cherubini, L. Techner, W. Du, Y. Ma, W. Schmidt, B. Wallin, D. JacksonVolume:
5
Year:
2004
Language:
english
DOI:
10.1016/j.jpain.2004.02.196
File:
PDF, 54 KB
english, 2004